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Male hypogonadism now has a new spectrum of complications. They are mainly cardiometabolic in
nature. Low serum testosterone levels are a risk factor for diabetes, metabolic syndrome,
inflammation and dyslipidemia. These metabolic and inflammatory complications are not without
consequences. Recent studies have shown low serum testosterone levels to be an independent risk
factor of cardiovascular and all-cause mortality. It is time to welcome low serum testosterone levels
as a cardiovascular risk factor.
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Testosterone is the predominant sex hormone in
man. Ayoung man produces 3–10mg of testosterone
daily that results in serum levels of 300–1000ng per
100ml. The traditional consequences of male hypo-
gonadism are well known. These include decreased
libido, erectile dysfunction, decreased muscle mass
and strength, increased fat mass, changes in mood
and energy, osteoporosis and decreased sexual hair.
1
However, for the past two decades, many studies
have found an association between low serum
testosterone levels and various cardiovascular (CV)
risk factors. In addition, some epidemiological
studies have also linked low testosterone levels
with CV and all-cause mortality. In this review, we
will briefly touch upon the various CV risk factors
that have been linked to low serum testosterone in
men.
Diabetes and metabolic syndrome
Low testosterone levels have been associated with
diabetes and metabolic syndrome. Epidemiological
studies have reported that low testosterone levels
are an independent risk factor for type-2 diabetes.
2
Interestingly, concentrations of free and bioavailable
testosterone even in the low-normal range are
associated with diabetes, after adjusting for adipos-
ity.
3 Similarly, low total testosterone levels inde-
pendently predict development of the metabolic
syndrome in middle-aged men.
4 Interventional trials
have shown that testosterone administration results
in an increased glucose uptake by the muscles,
thereby improving insulin sensitivity.
5 One study
even showed an improvement in HbA1c in hypogo-
nadal men with type-2 diabetes who received
testosterone.
6 Another study showed that testoster-
one replacement inhibits incorporation of triglycer-
ides in visceral fat (which is the most active depot
metabolically and contributes to insulin resis-
tance).
7 In addition, androgen deprivation in men
with prostate cancer is associated with hyperglyce-
mia and metabolic syndrome,
8,9 and the degree of
hyperglycemia is directly related to the duration of
castration.
10 Thus, even low-normal levels of testos-
terone appear to be a risk factor for metabolic
dysregulation.
Hyperlipidemia and inflammation
In contrast to the belief of many physicians that
androgen administration leads to an adverse lipid
profile, research shows that physiological testoster-
one replacement is at least neutral (if not beneficial)
to lipids. Hence, it should be differentiated from
non-aromatizable androgens that do result in harm-
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protein. Epidemiological data suggest that testo-
sterone levels are associated negatively with total
cholesterol, low-density lipoprotein cholesterol and
triglycerides, and positively with high-density lipo-
protein cholesterol.
11 Trials of testosterone replace-
ment have shown an improvement in lipid profile.
12
Similarly, there are reports of inverse associations
between inflammatory cytokines and testosterone,
13
and a reduction in these cytokines is seen with
testosterone replacement.
12 Furthermore, inverse
associations have been found between testosterone
and plasminogen activator inhibitor I, fibrinogen
and factor VII.
14
Atherosclerosis
Studies show that low testosterone levels are
associated with atherosclerosis in all major vessels.
Animal experiments have shown that testosterone
inhibits plaque development in rabbits and rodents
fed a high-fat diet.
15 It was Phillips et al.
16 who first
reported an inverse relationship between low total
and free testosterone levels and angiographically
proven coronary artery disease after adjusting for age
and adiposity. A recent study confirmed these
findings, showing that men with coronary artery
disease had lower levels of testosterone than con-
trols and that testosterone levels were inversely
correlated to the degree of coronary atherosclero-
sis.
17 In the Rotterdam study, the association
between total and bioavailable testosterone and
aortic atherosclerosis was evaluated in 504 non-
smoking men aged X55 years.
14 They found that
men in the highest tertile had a risk reduction of 60–
80% of severe aortic atherosclerosis after controlling
for age and CV risk factors. Another prospective
study of elderly men (mean age 77 years) showed
free testosterone to be inversely related to the
progression of intima–media thickness of the com-
mon carotid artery over 4 years.
18 Furthermore, men
in the lowest tertile of testosterone experienced
more progression.
Vascular tone and endothelial function
The vascular system is a target of androgen action
and current evidence suggests that androgens are
beneficial to vasculature. Older studies conducted
more than six decades ago showed that testosterone
replacement relieved symptoms of angina and
peripheral vascular disease.
19 Similarly, population
studies have shown that systolic and diastolic blood
pressures are inversely correlated with testo-
sterone.
20 Recent animal studies show that acute
treatment with testosterone results in dilatation of
the coronary and pulmonary arteries.
21 In humans,
transdermal testosterone therapy improves exercise-
induced myocardial ischemia (measured as time to
ST depression) during an exercise stress test in men
with stable angina,
22 with men having the lowest
baseline testosterone levels benefitting the most. A
recent study using oral testosterone in hypogonadal
men with coronary artery disease showed increased
myocardial perfusion.
23 These vasodilatory effects
of testosterone are reflected by the fact that men
with prostate cancer undergoing androgen depriva-
tion therapy experience arterial stiffness.
24 It is
believed that testosterone causes both endothe-
lium-dependent and endothelium-independent va-
sodilation. The former is achieved by an increased
release of nitric oxide from endothelium, whereas
the latter by blocking of calcium channels and/or
opening of potassium channels
25 (Figure 1). Recent
studies also suggest a beneficial role for testosterone
in endothelial regeneration.
26 Testosterone replace-
ment in hypogonadal men results in an increase in
the number of circulating endothelial progenitor
cells.
27 This increase is androgen receptor mediated
(not a result of rise in estrogen levels) as this event is
abolished by androgen receptor antagonists.
28
Mortality
Recent population studies have shown that low
serum testosterone levels are associated with both
CV and all-cause mortality. A retrospective study of
male veterans showed that low testosterone was
associated with increased mortality.
29 A prospective
study of 794 men, aged 50–91 years, looked at the
relationship of testosterone with all-cause mortality
over two decades.
30 Men with total testosterone
levels in the lowest quartile (o241ng per 100ml)
were 40% more likely to die than men with higher
androgen levels, independent of age, adiposity,
lipids, adipokines and lifestyle. In cause-specific
analyses, low testosterone predicted increased risk
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Figure 1 Action of testosterone on calcium and potassium
channels.
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recent study, Khaw et al.
31 conducted a nested case–
control study to determine the association of
endogenous serum testosterone with all-cause, CV
and cancer-related mortality. The authors compared
825 men who did not have any CV disease or cancer
at baseline but died during the course of follow-up,
with 1489 men who were still alive. The cases and
controls were matched for age and date of baseline
visit. The authors found that baseline testosterone
levels were inversely related to deaths due to all
cause, CV disease and malignancy. This protective
effect of testosterone increased with increasing
quartiles such that men in the highest quartile had
30% lower risk of death compared with those in the
lowest quartile. Similarly, men undergoing andro-
gen deprivation therapy for prostate cancer are also
at risk of increased CV mortality compared with
men not undergoing castration.
32
Conclusion
This review shows that ample evidence has accu-
mulated through epidemiological studies and small
clinical trials showing that low androgen levels are
associated with numerous CV risk factors and
mortality (Figure 2). In addition to traditional CV
risk factors, novel risk factors are also inversely
related to testosterone levels. Indeed, a recent study
showed that low testosterone levels increase oxida-
tive stress in men and testosterone replacement
reverses this pathology.
33 Similarly, the effect of
testosterone treatment in men with chronic heart
failure is also being explored.
34 Now what we need
are long-term, double-blind, randomized, placebo-
controlled trials of androgen replacement in men
with low testosterone levels and evaluate its effect
on CV risk factors, CV mortality and all-cause
mortality. What we need is a Men’s Health Initiative
study and the federal funding agencies should be
open to this kind of trial. In the meantime, we
should consider welcoming low testosterone as a
new CV risk factor in men.
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